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Caveolin-1 (Cav-1) plays an important role in modulating cellular signalling, but its role in metastasis is not well defined. A significant
reduction in Cav-1 levels was detected in lymph node metastases as compared with primary tumour of head and neck squamous cell
carcinoma (HNSCC) specimens (Po0.0001), confirming the downregulation of Cav-1 observed in a highly metastatic M4 cell lines
derived from our orthotopic xenograft model. To investigate the function of Cav-1 in metastasis of HNSCC, we compared stable
clones of M4 cells carrying human cav-1 cDNA (CavS) with cells expressing an empty vector (EV) in vitro and in the orthotopic
xenograft model. Overexpression of Cav-1 suppressed growth of the CavS tumours compared with the EV tumours. The incidence
of lung metastases was significantly lower in animals carrying CavS tumours than those with EV tumours (P¼0.03). In vitro, CavS cells
displayed reduced cell growth, invasion, and increased anoikis compared with EV cells. In CavS cells, Cav-1 formed complex with
integrin b1 and Src. Further application of integrin b1 neutralising antibody or Src inhibitor PP2 to EV cells illustrated similar
phenotypes as CavS cells, suggesting that Cav-1 may play an inhibitory role in tumorigenesis and lung metastasis through regulating
integrin b1- and Src-mediated cell–cell and cell–matrix interactions.
British Journal of Cancer (2008) 99, 1684–1694. doi:10.1038/sj.bjc.6604735 www.bjcancer.com
Published online 28 October 2008
& 2008 Cancer Research UK
Keywords: squamous cell carcinoma of the head and neck; caveolin-1; integrin b1; Src
                                                 
Caveolin-1 (Cav-1) is a 21–24kDa integral membrane protein and
a principal structural component of caveolae. A scaffolding amino-
acid sequence identified in Cav-1 allows this protein to interact
with signalling molecules such as epidermal growth factor
receptor, G-proteins, c-Src-like kinases, HA-Ras, protein kinase
C, endothelial nitric-oxide synthase, and integrin (Razani et al,
2001; Liu et al, 2002). Substantial evidence of increased expression
of Cav-1 associated with tumour progression and metastasis has
been established mostly in prostate cancer (Williams et al, 2005).
In contrast, it has been suggested that Cav-1 acts as a putative
tumour and metastasis suppressor of breast cancer (Sloan et al,
2004; Williams et al, 2004; Williams and Lisanti, 2005), indicating
that the role of Cav-1 in metastasis is cell-type specific and remains
to be defined. Thus, comprehensive studies of the loss of Cav-1
expression and the role of Cav-1 in metastasis development are
lacking.
Squamous cell carcinoma (SCC) represents more than 90%
of head and neck (HN) malignant tumours. Development of
metastasis, particularly distant metastasis, is a major obstacle to
the successful treatment of these patients. However, the genetic
mechanisms contributing to behaviour of metastatic cells in
human HNSCC are not well understood. A unique metastasis
mouse model established in our laboratory represents a late stage
of metastasis development in human HNSCC (Zhang et al, 2002).
Cell lines derived through the fourth round of in vivo selection
generated a significantly greater incidence of lymph node and lung
metastases than their parental cells (Zhang et al, 2006). cDNA
microarray analysis of both non-metastatic and highly metastatic
HNSCC cells revealed that significant downregulation of Cav-1 and
-2, loss of E-cadherin and p53 and a marked increase in integrin b1
protein levels were associated with highly metastatic behaviour
(Zhang et al, 2006). In addition, differentially altered proteins
identified from the cDNA microarray analysis, including
E-cadherin, EGFR, S100A2, protease-activated receptor-1, and
CCR7, were confirmed in human HNSCC tissue samples (Wang
et al, 2004; Zhang et al, 2004a, 2007; Muller et al, 2008). These
observations suggest that this model represents at least one
population of metastatic HNSCC cells, thus providing an excellent
means to examine the role of Cav-1 in tumour progression and
metastasis potential in HNSCC.
By using a HNSCC metastasis animal model, this study presents
that the downregulation of Cav-1 observed in cell lines derived
from the in vivo selection is consistent with that in human tissue
specimens. Expression of Cav-1 was inversely associated with
metastasis of HNSCC, but positively associated with tumour
differentiation. Further in vitro studies revealed that Cav-1 protein
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scan directly interact with integrin b1 and Src, thus disrupting
integrin b1/Src-mediated tumour cell growth, invasion, and
survival during metastasis. Most importantly, the study has
revealed the novel findings of the differential effect of Cav-1 on
lymph node and lung metastasis in the animal model. Over-
expression of Cav-1 sensitises metastatic cells to anoikis,
ultimately leading to reduced lung metastasis.
MATERIALS AND METHODS
Tumour specimens and patient information
Consent for tissue acquisition was approved by Institutional
Review Board of University of Pittsburgh. A total of 114 specimens
were randomly collected from surgical specimens obtained
between 1983 and 1993. Requirements for inclusion in the study
included no previous radiation or chemotherapy treatment before
the resection and that paraffin blocks were available for study. The
collected formalin-fixed paraffin-embedded tissue blocks consisted
of three groups: primary tumours with positive lymph nodes
(Tu-1), their paired lymph node metastases (LNM-1), and primary
tumours with negative lymph nodes (Tu-2). The number
of samples and distribution were n¼34 (Tu-1), n¼40 (LNM-1),
n¼40 (Tu-2). Tumour grade was categorised as poorly
differentiated (PD), moderately differentiated (MD), and well
differentiated (WD) by two pathologists (SM and HJCS) indepen-
dently. Eleven normal oral epithelial tissue samples from
non-cancer patients were used as a control. The clinical informa-
tion was available for some of the samples (n¼57) and was
obtained from the surgical pathology files at the University of
Pittsburgh, following the regulations of the Health Insurance
Portability and Accountability Act. Of these patients, 17 had stage
T1–T2 and 23 had T3–T4 disease. Primary tumour sites included
oral cavity (floor of mouth, tongue, retromolar trigone, and
alveolar ridge, n¼16), pharynx (soft palate, base of tongue, and
posterior wall of pharynx, n¼6), and larynx (aryepiglottic fold,
glottis, epiglottis, subglottic, and transglottic, n¼18). There were
equal numbers of males and females with an average age of 61.2
years and median months of follow-up 72 (ranging from 8 to 172
months). At the time of data collection, 9 patients showed no
evidence of disease, 12 had died of complications, and 16 had died
of disease.
Cell lines
The HNSCC cell line 686LN was established from a lymph node
metastasis of a primary base of tongue tumour (Sacks, 1996).
686LN has a low capability for metastasis to the lymph node and
none to the lung in nude mice as described previously (Zhang et al,
2002, 2006). Derived through in vivo selection in nude mice from
the parental 686LN cells, 686LN-M3s (M3s), and 686LN-M4s
(M4s) cells, including the clones M3a, M3b, M4c, M4d, and M4e,
are highly metastatic cell lines capable of generating high
incidences of lymph node and lung metastases. The cell lines were
maintained as monolayer cultures in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 medium (1:1) supplemented with 10%
fetal bovine serum (FBS) at 371C in a humidified atmosphere with
5% CO2.
Chemicals and antibodies
Antibodies and their sources were as follows: polyclonal anti-Cav-1
(sc-894), -MMP-2, and -p27 were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA); monoclonal anti-Cav-1,
-integrin b1, and -p21 were from BD Transduction Laboratories
Inc. (Lexington, KY, USA); inhibitory integrin b1-blocking
antibody (P4C10) and anti-MT-MMP1 were from Chemicon Inc.
(Temecula, CA, USA); antibodies against caspase 8, caspase 9,
PARP, survivin, E2F1, phospho- and total ERK, Src and Rb were
from Cell Signaling (Beverly, MA, USA). Monoclonal anti-pro and
-cleaved caspase 3 were purchased from Imgenex (San Diego, CA,
USA). Monoclonal anti-carcinoembryonic antigen (CEA) was from
ABCAM Inc. (Cambridge, MA, USA). Specific inhibitor PP2 and
U0126 were procured from Calbiochem (San Diego, CA, USA).
5-Aza-20-deoxycytidine (5-aza-dc) was from Sigma (Missouri, MO,
USA). Alexa Fluor 488 and 568 conjugated goat anti-mouse and
goat anti-rabbit, respectively, were from Molecular Probes
(Eugene, OR, USA). Annexin V and 7-amino-actinomycin D were
purchased from BD PharMingen (San Diego, CA, USA). Detection
of apoptosis was performed with terminal transferase dUTP nick
end labelling (TUNEL) kit (Promega, Madison, WI, USA).
Immunohistochemistry
Antigen retrieval was achieved by microwaving the deparaffinised
formalin-fixed human tumour tissue sections. Sections were
incubated with 1:200 dilution of anti-Cav-1 at 41C overnight.
Detection was achieved with the Vector avidin–biotin complex
system (Vector Laboratories, Burlingame, CA, USA). For Cav-1
staining, rabbit IgG was used as a negative control and staining of
endothelial cells was used as a positive control. The intensity of
immunohistochemical staining in human tissues was measured
using a numerical scale (0¼no expression, 1
þ ¼weak expression,
2
þ ¼moderate expression, and 3
þ ¼strong expression which is
similar to or stronger than the staining of endothelial cells) and
quantified as Weight Index (WI¼% positive staining (40) in
tumour intensity score). Scoring was performed independently
by two pathologists (SM and HJCS). An average of the two
readings was used for statistical analysis.
Stable transfection of Cav-1 cDNA in HNSCC cells
The plasmid lenti-cav-1 was constructed following the protocol
described previously (Liu et al, 2006). Briefly, the human cav-1
cDNA was amplified by standard reverse transcription–PCR from
RNA extracted from 686LN cells using the following primers:
Cav-1 sense: 50-GACTAGTGCCGCCACCATGTCTGGGGGCAAA
TACGTAG-30,
reverse: 50-CGGGCCCTTATATTTCTTTCTGCAAGTTGATGCGG-30.
The cav-1 cDNA was then ligated into the pT-easy vector
(Promega) as pTeasy-cav-1 following the manufacturer’s protocol.
pT-easy-cav-1 was cut with SpeI and ApaI, and the released
fragment containing cav-1 cDNA was then cloned into the digested
pLenti6/V5 vector and the resulting construct was named CavS.
The coding region of cav-1 cDNA was confirmed by sequencing
analysis. The empty pLenti6/V5 vector was used as a control.
Lentiviral production and titre determination were previously
described (Liu et al, 2006). For infection, virus was added to M4
cells at a multiplicity of infection of 10, and the cells were then
subjected to selection with 25mgml
 1 blasticidin 24h post-
infection. Fourteen days later, the cell clones were picked and
screened for Cav-1 expression by immunoblotting.
HNSCC metastatic xenograft mouse model
The animal experiment was approved by the Animal Care and Use
Committee of Emory University. Twenty-two nude mice (athymic
nu/nu, Taconic, NY, USA) aged 4–6 weeks (about 20g body
weight) were randomly divided into two groups. Each animal was
injected with 1 10
6 EV or CavS cells suspended in 0.05ml of
Hanks-buffered saline into the submandibular to mylohyoid
muscle as described previously (Zhang et al, 2002). The xenograft
tumours were measured three times per week. After mice were
killed, cervical lymph nodes and lungs were collected, fixed
immediately in 10% buffered formalin, and embedded in paraffin.
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sTissue sections were stained with hematoxylin–eosin and anti-
CEA antibody. Lymph node and lung metastases were identified by
a pathologist (SM).
Cell proliferation sulforhodamine B (SRB) assay
Cells were seeded at 2 10
3 per well in 96-well plates and
incubated for 7 days with four repeats per treatment. After fixation
in 10% trichloroacetic acid for 1h at 41C, the cells were stained
with 0.4% SRB in 1% acetic acid for 10min followed by washing
with 1% acetic acid and air-drying. Sulforhodamine B bound to
cellular protein was dissolved in 10mM Tris-HCl (pH 10.5). The
protein level was measured by spectrophotometry at 492nm and
expressed as number of cells proportional to protein level.
Experiments were repeated four times.
Matrigel invasion assay
Matrigel was purchased from Becton Dickinson Biosciences
Discovery Labware (Bedford, MA, USA). The Matrigel invasion
assay has been described previously (Zhang et al, 2002). Briefly,
2.5 10
4 cells per well were seeded in triplicate with serum-free
medium containing 0.1% BSA in the invasion chamber (BD
Biosciences, Bedford, MA, USA) precoated with 27.2mg per
chamber of Matrigel for 8h before the NIH-3T3-conditioned
medium was added to the lower chamber. In some experimental
groups, cells were preincubated with mouse IgG, integrin b1
neutralising antibody (0.5mgml
 1), PP2, or U0126 at 5mM for 2h at
room temperature before being added to the wells. After 36–40h
of incubation, the upper membrane (8-mm pore size) was gently
scrubbed with a cotton swab. The invaded cells in the lower
membrane were stained with the Hema-3 kit, following the
manufacturer’s instructions (Fisher Scientific, Pittsburgh, PA,
USA). The number of invaded cells was expressed as the sum of
10 random fields under the microscope at  200 magnification.
Experiments were repeated three times.
Demethylation assay
The parental 686LN and its metastatic derivatives from the third
and fourth rounds of in vivo selection 686LN-M3s and 686LN-M4s,
respectively, were treated with or without 5-aza-20deoxycytidine
(5-aza-dc, 5mM) for 4 days. Total protein of the lysates was
analysed for Cav-1 with G3PDH as a loading control by
immunoblotting. The experiment was repeated twice.
Anoikis assay
To prevent cell adhesion, HNSCC cells were cultured onto a plastic
bacteriological Petri dish precoated with poly-HEMA (Fiucci et al,
2002). Cells were plated at a density of 2 10
6 per well in a six-well
plate for 24–48h. The survival of attached and suspended cells was
determined by flow cytometry analysis of annexin V and 7-amino-
actinomycin D staining. Experiments were performed in triplicate
and repeated twice.
For integrin b1-blocking antibody experiment, serum-starved
cells were preincubated with control mouse IgG or the blocking
antibody (P4C10, 0.5 or 1.0mgml
 1) for 2h at room temperature
before they were suspended for 48h. The suspended cells were
then placed onto 0.01% of poly-lysine-coated glass slides and fixed
with 4% paraformaldehyde and 0.5% Triton-X 100 for 10min at
room temperature. Double immunofluorescence staining is
described in the following section. Apoptosis was assessed by
performing the TUNEL assay according to the manufacturer’s
instructions (Promega).
Immunoblotting, coimmunoprecipitation, and
immunofluorescence analyses
Cell lysates containing equal amounts of protein were separated by
12% SDS–PAGE. Immunoblotting was carried out according to a
standard procedure. Protein assays were performed using a
modified Lowry procedure with a commercially available kit
(Bio-Rad, Hercules, CA, USA). For coimmunoprecipitation, about
500mg of lysate was precleared with recombinant protein G-
agarose (GIBCOBRL, Carlsbad, CA, USA) for 4h at 41C, incubated
with 5mg of antibody or non-immunised rabbit or mouse IgG
precomplexed with protein G-agarose overnight. Denatured
samples were separated by 12% SDS–PAGE.
For immunofluorescence staining, cells grown on coverslips
were fixed with warm PHEMO buffer (68mM PIPES, 25mM
HEPES, pH6.9, 15mM EGTA, 3mM MgCl2, 10% (vol/vol) DMSO)
containing 3.7% formaldehyde, 0.05% glutaraldehyde, and 0.5%
Triton X-100 for 10min and incubated with primary antibody and
fluor-conjugated secondary antibodies. Images were taken with
Zeiss LSM510 META confocal microscope.
Statistical analysis
For human tissues, expression values were averaged to yield a
single expression value when multiple metastatic nodes were
collected on a given individual. Nonparametric methods using the
Kruskal–Wallis and Mann–Whitney tests were performed to
compare WI among different groups. Wilcoxon signed-rank test
was applied for comparing paired samples Tu-1 and LNM-1. The
incidence of metastases was analysed by w
2 analysis or Fisher exact
test.
The statistical significance of treatment of cells in cell growth,
invasion, anoikis assay, and the number of metastatic cells was
assessed using the Student’s t-test. Po0.05 was considered
statistically significant in all analyses.
RESULTS
Expression of Cav-1 in human HNSCC tumours
The downregulation of Cav-1 observed in cell lines derived from
the HNSCC metastatic mouse model (Zhang et al, 2002, 2006) led
us to examine Cav-1 expression in primary tumours and LNM of
HNSCC tissue specimens by immunohistochemical analysis. The
tissue samples included three categories Tu-1 (primary tumours
from patients who also had LNM), LNM-1 (LNM samples from the
Tu-1 patients), and Tu-2 (primary tumours from patients who did
not have LNM; see Materials and Methods for details). The
specificity of Cav-1 immunoreactivity was examined by using
endothelium known to be abundant in Cav-1 as a positive control
and rabbit IgG as a negative control (Figure 1A top). The tumour
adjacent-normal (AN) tissues and 11 normal epithelial tissues from
non-cancer patients (NN) were also examined as the normal cell
controls (Figure 1A top). Caveolin-1 was mainly located at the
membrane and in the cytoplasm of the tumour cells as well as in
the endothelial cells. Expression of Cav-1 was barely detected in
the normal epithelium. In tumour tissues, a typical peripheral
staining pattern (Figure 1A middle and bottom) was frequently
observed in which Cav-1 immunoreactivity was seen in only the
outer cell layer of the nest, whereas the rest of the keratinocytes
and necrotic cells were negative.
Quantitative analysis of Tu-1, LNM-1, and Tu-2 samples
revealed that expression of Cav-1 was significantly downregulated
in LNM-1 compared with primary tumours (median WI¼82.5 for
LNM-1 vs median WI¼127 for Tu-1 and 140 for Tu-2, Po0.0001)
(Figure 1B left). Among 30 PD, 67 MD, and 17 WD tumour
samples, the expression of Cav-1 was lowest in the PD category
(Po0.0001) (Figure 1B, right). Table 1 shows the number of cases
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Figure 1 Immunohistochemical staining of Cav-1 in HNSCC specimens. (A) Immunohistochemical staining of Cav-1 in NN and AN (top), PD, MD, and WD of
primary tumours (middle) and of lymph node metastases (bottom). Staining with IgG was used as a negative control. Magnification was  200. (B) Quantified
analysis of Cav-1 expression with bar graph presentation of WI of Cav-1 vs tumour category and differentiation in tumour samples including Tu-1, -2, and LNM-1.
The line within the bar represents the median value and * represents individual data point. Expression of Cav-1 was significantly downregulated in LNM-1
compared to primary tumours (Po0.0001). Expression of Cav-1 was significantly lower in PD category than in MD and WD (Po0.0001). (C)G r o w t ho ft u m o u r s
in animals injected with EV cells or CavS cells. Tumour volume (mm
3) was recorded on every other 3 days post-tumour cell injection. Inserted figure shows the
representative tumour size from tumours bearing CavS (left) and EV (right) cells. CavS tumour volume was substantially reduced compared with EV tumours
(P¼0.0003 by day 25, P¼0.003 by day 39). The right panel shows representative immunohistochemistry staining of Cav-1 in EV and CavS-bearing tumours.
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scategorised by tumour differentiation status and tumour sites. It is
noticed that LNM-1 had more cases of PD than Tu-1 and Tu-2.
Pairwise comparison detected significantly lower Cav-1 expression
in LNM-1 compared with Tu-1 samples (n¼31, P¼0.0002).
Analysis of patient clinical information revealed that the WI of
Cav-1 inversely correlated with N-stages identified by histology (N
positive¼N1þN2þN3, n¼18, and N negative¼N0, n¼22,
P¼0.043), but did not correlate with T-stage, tumour site, patient
age, or survival rate.
Effect of Cav-1 overexpression on tumorigenicity and
metastasis in vivo
The role of Cav-1 expression in tumorigenesis and metastasis was
investigated by establishing stable M4 clones infected with
lentivirus expressing a full-length cav-1 cDNA (CavS). Stable cell
lines transfected with the empty vector (EV) were used as control.
The level of Cav-1 protein expression in CavS cells was comparable
to that in the parental 686LN cells with low metastatic potential
(data not shown).
To determine the effect of restoring Cav-1 expression in
metastatic cells on tumorigenesis and metastasis development, 22
nude mice were injected with 1 10
6 EV cells (n¼12) or high
Cav-1 expressing CavS cells (n¼10) (Zhang et al, 2002). To detect
tumour progression, metastasis development, and the level of
Cav-1 expression, half of the animals were killed on day 25 post-
injection and the rest were killed on day 39 post-injection. Tumour
volume was substantially reduced in animals injected with CavS
cells compared with those injected with EV cells (P¼0.0003 by day
25, P¼0.003 by day 39, Figure 1C left). By day 39, tumour weights
were 1.02±0.39 and 0.26±0.16g for tumours bearing EV and CavS
cells, respectively (P¼0.001). With endothelial cells as a positive
control, Cav-1 staining was detected in all tumour cells of the CavS
tumour tissues but was negative in all tumour cells of the EV
tumour tissues (Figure 1C right). There was no significant
difference in Cav-1 expression among tumour samples collected
from two time points. All animals in both groups had identifiable
LNM by days 25 and 39. When taken together, 9 out of 12 mice
injected with EV cells had lung metastases, whereas 3 out of 10
mice injected with CavS cells had positive lung metastases
(P¼0.03 by w
2 and P¼0.08 by Fisher exact test when the small
sample size was considered). In addition, the number of metastatic
foci identified microscopically and highlighted with CEA staining
was significantly lower in animals injected with CavS cells (Table 2,
P¼0.03). TUNEL assay revealed no difference in the amount of
TUNEL-positive areas, including apoptotic and necrotic signals,
between EV and CavS tumours (data not shown).
Effect of Cav-1 overexpression on cell proliferation and
invasion in vitro
Silencing of gene expression frequently occurs because of
promoter hypermethylation. Thus, we investigated whether the
downregulated expression of Cav-1 in the highly metastatic cell
lines was due to methylation of the cav-1 promoter or was the
secondary effect of hypermethylation of certain Cav-1-regulatory
genes. Treatment with the demethylation agent 5-aza-dc substantially
restored the expression of Cav-1 in highly metastatic cells to a
level similar to that in the parental 686LN cell (Figure 2A), but
promoter hypermethylation of Cav-1 in the tested cell lines was not
detected by methylation-specific PCR (Dr P Vertino, personal
communication).
To understand the inhibitory effect by Cav-1 observed in the
xenograft mouse model, we first examined growth rate of both EV
and CavS cells. Clones of high Cav-1 expressing cells (CavS-H,
similar to the levels of parental 686LN) and low Cav-1 expressing
cells (CavS-L, 25–50% of the levels in CavS-H) were selected.
Consistent with the observation in vivo, the in vitro cell growth
rate was substantially curtailed in CavS cells compared with a pool
of EV cells (Figure 2B), with 25 and 48% reductions in CavS-L
(P¼0.0027) and CavS-H (P¼0.0001), respectively. To dissect the
mechanism underlying the inhibitory actions of Cav-1 in
tumorigenesis, typical Cav-1 targeting signalling molecules,
including the activation of Src and ERK (Williams and Lisanti,
2005), were examined among CavS-L and CavS-H cells. Interest-
ingly, activation of Src and ERK were substantially diminished in
both low and high CavS expressing clones (Figure 2C). Some
proteins involved in cell cycle regulation, such as p21, p27, E2F,
and Rb, were also affected by restoration of Cav-1. To elucidate
whether the ERK or Src signalling pathways play a role in growth
of M4 cells, we also found that cell growth of a pool of EV cells was
markedly inhibited by Src kinase inhibitor PP2, and moderately by
ERK kinase inhibitor U0126 (Figure 2C).
We then examined the effect of restoration of Cav-1 on cell
invasion by Matrigel invasion assay. Compared with a pool of EV
cells, CavS-L and CavS-H cells showed 65.5 and 76.3% reduction in
invasion, respectively (Po0.0001, Figure 3A). It was suggested that
Cav-1 mediated anchorage-dependent cell growth by acting as an
adaptor between integrin b1 and the Src family kinase Fyn (Wary
et al, 1998). A previous study has also shown that phosphorylation
of integrin b1 at serine 785 inhibits cell migration (Mulrooney
et al, 2001). Thus, in addition to examining the involvement of
ERK and Src signalling pathways on invasion, the overexpression
of integrin b1 in M4 cells compared with their parental 686LN
cells (Zhang et al, 2006) led us to investigate whether integrin
b1-dependent functions could be modulated by Cav-1. The
Matrigel invasion assay was performed with EV cells treated with
integrin b1-blocking antibody at 0.5mgml
 1, PP2 and U0126 at
5mM along with CavS-L and CavS-H cells. These concentrations did
not generate noticeable apoptosis (data not shown). Similar to our
observations on cell proliferation, the invasion activity of EV cells
was markedly suppressed by the application of PP2 and integrin
b1-blocking antibody, and moderately inhibited by U0126
(Figure 3A).
Table 1 Number of cases in tumour differentiation status and tumor
sites
Total¼114 WD¼17 MD¼67 PD¼30
T1¼34 3 20 11
T2¼40 10 27 3
LNM-1¼40 4 20 16
Table 2 Number of invaded tumour cells identified in the lung tissues
Days post-
injection
EV animal
tag no.
Number of
cells
CavS animal
tag no.
Number of
cells
25 159 0 166 0
174 0 169 0
153 18 172 0
154 13 163 1
156 42 173 5
158 12
39 151 0 89 0
91 21 161 0
152 7 165 0
155 61 90 2
157 10 170 25
160 36
The number of metastatic foci highlighted with CEA staining was significantly lower in
animals injected with CavS cells (P¼0.03).
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cells were also examined. Sum of invaded cells over 10 random fields was recorded. Invasion activity was significantly impaired in the treated cells and CavS
cells compared with that in EV cells (Po0.0001). Experiments were performed three times. (B) Immunoblotting analysis of the proteins associated with
invasion in EV, CavS-L, and CavS-H. (C) Immunoblotting analysis of EV cells treated with integrin b1-blocking antibody (mgml
 1) or PP2 (mM). (D) Cav-1
coimmunoprecipitated with Src and integrin b1. Experiments were performed three times.
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sThe suppression of invasion activity in CavS cells was correlated
with the expression of Cav-1 protein, and associated with increased
serine 785 phosphorylation of integrin b1 and decreased
active MT1-MMP and MMP2 (Figure 3B) in addition to the
substantially suppressed activation of Src and ERK (Figure 2C).
Similarly, immunoblotting analysis revealed that inhibited
invasion activity of EV cells by integrin b1-blocking antibody
was associated with markedly increased phosphorylated integrin
b1 (ser785) at 0.5mgml
 1, completely diminished activation of
Src, Rb and inhibited active MT1-MMP (Figure 3C). PP2
completely diminished activation of Src, moderately suppressed
the active MT1-MMP at a higher dose and reduced phospho-Rb
without affecting phosphorylation of integrin b1 (ser785).
Furthermore, we indeed observed that Cav-1 could coimmuno-
precipitate with integrin b1 and Src in CavS cells (pool of CavS-H
and CavS-L clones, Figure 3D) and the parental 686LN cells (data
not shown).
Overexpression of Cav-1 on anoikis
M4 cells have acquired anoikis-resistance compared with parental
686LN cells (Zhang et al, 2006). When M4 cells were in suspension,
they tended to form aggregates to sustain survival. Their lack of
E-cadherin and Cav-1 while possessing high levels of integrin
b1(Zhang et al, 2006) led us to hypothesise that loss of Cav-1 may
facilitate integrin b1-mediated cell–cell contact by forming
aggregates, leading to escape from anoikis. To test this hypothesis,
we first performed anoikis assay to compare EV and CavS
cells. When EV and CavS cells were deprived from attachment to
matrix for 48h, CavS cells exhibited 51.4% (Po0.01) greater
apoptosis than EV cells. Figure 4B shows a representative
distribution of the apoptotic cell population from the flow
cytometry analysis. As the result of marked increase in anoikis,
higher levels of cleaved caspases 3, 8, and PARP were detected in
CavS-H cells than in EV cells (Figure 4C). Survivin protein
expression was barely detectable in CavS-H cells under suspension
conditions (Figure 4C).
We then asked whether the direct interaction of Cav-1 with
integrin b1 may modulate integrin b1-mediated survival in M4
cells. We observed that the formation of aggregates in suspended
CavS cells was less than that in EV cells (data not shown).
Immunofluorescence staining revealed that a membranous
distribution of integrin b1 was detected in the attached cells, but
intensely accumulated at cell–cell junctions in the suspended EV
cells (Figure 5). In the presence of CavS cells, integrin b1 exhibited
noticeable internalisation and colocalised with Cav-1 protein both
in the membrane and the cytoplasm under either attached or
suspension conditions. Similarly, when integrin b1-blocking anti-
body was applied to EV cells in suspension for 48h, it was found
that aggregate formation was substantially inhibited (Figure 6A).
Integrin b1-blocking antibody induced significant dose-dependent
increases in apoptosis detected by TUNEL assay (Figure 6B,
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Figure 4 Effect of reintroducing Cav-1 on anoikis. (A) Flow cytometry analysis of apoptosis between attached and suspended EV and CavS cells (various
high and low Cav-1 expressing clones). Cells were allowed to attach or suspend in the culture dishes for 48h. The survival of attached and suspended cells
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conditions, respectively, than the EV cells. (B) Representative of flow cytometry analysis shows distribution of apoptotic cells in the attached and suspended
conditions. (C) Activation of caspases detected by immunoblotting in EV, CavS-L, and CavS-H cells under 48h of suspended or attached condition. Figure
was shown as representative from three independent experiments.
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sP¼0.04), increased cleavage of caspases 9, 8, 3 and PARP, and
decreased phosphorylated Src compared with cells treated with IgG
control (Figure 6C).
DISCUSSION
Studies supporting Cav-1 as a negative regulator of tumour
progression have been thoroughly reviewed (Williams and Lisanti,
2005). However, concrete evidence is lacking for a definite role
of Cav-1 not only in acquiring metastasis but also in metastatic
progression. Thus, this study was designed to examine the effect of
Cav-1 overexpression on tumour progression and metastasis
potential of HNSCC. Examination of human HNSCC tumour
tissues revealed significantly lower levels of Cav-1 in LNM than in
the primary tumours with and without LNM. This indicates that
the presence of Cav-1 in cells with low metastatic potential and the
loss of Cav-1 in highly metastatic cells observed in our model may
represent HNSCC metastasis development. Thus by using this
highly metastasis xenograft mouse model, we were able to show
that restoration of Cav-1 protein expression substantially reduced
tumour growth and inhibited lung metastasis. Further in vitro
studies revealed that restoration of Cav-1 protein significantly
inhibited metastatic cell growth and invasion, and sensitised
metastatic cells to anoikis, possibly through the interactions
of Cav-1 with integrin b1 and Src. On the basis of these findings, it
is plausible to suggest that restoration of Cav-1 could reverse
the aggressive behaviour of highly metastatic tumour cells by
modulating the vital integrin b1/Src-mediated cell–cell and
cell–matrix machineries, leading to suppression of tumour growth
and metastasis potential in late stage of tumour development
(Figure 7).
Loss of Cav-1 expression has been reported in oral SCC
metastatic lesions (Hung et al, 2003). The absence of significant
hypermethylation in cav-1 promoter and the restoration of Cav-1
expression after 4 days of demethylation treatment (Figure 2A)
indicate that the loss of Cav-1 expression could be a secondary
effect of hypermethylation of certain Cav-1 regulatory genes. We
did not observe any significant correlation of Cav-1 expression
with tumour stage and survival rate, as we were unable to stratify
the patients due to treatment and limited sample size. However, we
were able to assess the dynamic changes in Cav-1 protein
expression during metastasis by performing pairwise comparisons
of Cav-1 expression levels between primary tumours and LNM
from the same patient. The analysis revealed significant down-
regulation of Cav-1 in LNM and that Cav-1 expression was
inversely associated with N-stage and positively with tumour
differentiation. In contrast to our observation, a study of
oesophageal SCCs found that overexpression of Cav-1 was
associated with LNM and a worse prognosis after surgery (Kato
Integrin  1
EV
CavS
EV
CavS
Suspended
Attached
Merged Cav-1
Figure 5 The effect of direct association of Cav-1 with integrin b1 on integrin b1-mediated survival. Immunofluorescence staining of integrin b1 (the first
column), Cav-1 (middle column), and the merged images (the right column) of EV and CavS cells under attached (top) or suspended condition (bottom).
Image was taken with confocal microscopy (magnification  630).
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set al, 2002), suggesting that the effect of Cav-1 on metastasis
progression could be tissue-specific as illustrated in the contra-
dictory cases between breast cancer (Sloan et al, 2004) and prostate
cancer (Williams et al, 2005).
The interplay of Cav-1 with integrins could modulate integrin-
dependent tumour cell growth and invasion. Consistent with the
finding by Wary et al (1998), we observed that Cav-1 may be
capable of mediating integrin/Src-dependent cell growth and
invasion by interacting with integrin b1 and Src. Reduced cell
growth and invasion activity in CavS cells were associated with
increased phosphorylated integrin b1 (ser785) and completely
diminished activation of Src, similar to the effect of integrin b1-
blocking antibody and Src inhibitor PP2. Further evidence of the
interaction came from the findings that Cav-1 coimmunoprecipi-
tates with integrin b1 and Src, and the reduced levels of
membranous integrin b1 probably as a result of internalisation
by Cav-1 (Figure 5). This observation is consistent with the finding
that increased phosphorylated integrin b1 (ser785) leads to
reduced cell migration as a result of failure to form a focal
adhesion complex with integrin b1 (Mulrooney et al, 2001). These
data indicate that Cav-1 may directly affect integrin b1-dependent
cell growth, invasion, and survival through inside-out signalling.
Inhibition of EV cell growth and invasion induced by PP2
resembled the effect of integrin b1-blocking antibody, evidenced
by complete suppression of activated Src without the induction of
phosphorylated integrin b1 (ser785), indicating that Src activation
may be a downstream signalling consequence of integrin activa-
tion. Thus, the diminished phosphorylated Src in CavS cells could
be a result of both the direct interference by Cav-1 and indirect
consequence of the interaction between integrin b1 and Cav-1
(Figure 7). The pivotal roles of Src in cell growth and metastasis
has been well established (Yeatman, 2004). Significant enhance-
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 1 for 48h (magnification  40). (B) TUNEL-positive cells were quantified and
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Figure 7 Schematic model of Cav-1 in inhibiting tumour growth and
metastatic progression. In highly metastatic cells, loss of Cav-1 may facilitate
activation of integrin b1/Src-mediated biological activities, including cell
growth, invasion, and anoikis resistance. Restoration of Cav-1 could reverse
the aggressive behaviour of highly metastatic tumour cells by modulating
the vital integrin b1/Src-mediated cell–cell and cell–matrix machineries,
leading to suppression of tumour growth and metastasis potential. Solid line
and dashed line represent direct and indirect effect, respectively.
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sment of p21 and p27 levels associated with reduced cell growth in
CavS cells compared with EV cells could be further supported by a
recent study that Src stabilises p27 protein (Chu et al, 2007).
This study has demonstrated that Cav-1 suppresses anoikis
resistance, possibly by interfering integrin-mediated cell–cell
contact-dependent survival mechanism (Yu et al, 2000; Gross-
mann, 2002). It has been reported that human oral SCC cells could
evade p53-mediated anoikis by forming aggregates through av
integrin-fibronectin binding (Zhang et al, 2004b). Upregulated
integrin b1 in the metastatic HNSCC cells is associated with
increased anoikis resistance, invasion activity and much stronger
adhesion to fibronectin, a ligand for integrin b1, compared with
their parental 686LN cells (Zhang et al, 2002, 2006). The
application of integrin b1 functional-blocking antibody effectively
abolished cell aggregates, inducing substantial anoikis associated
with completely suppressed activated Src, suggesting that anoikis
resistance in M4 cells was achieved by an integrin b1/Src-mediated
cell–cell contact survival mechanism (Figure 6). The interaction of
Cav-1 with integrin b1 and with Src may reduce the cell–cell
contact (Figure 5), thus diminishing the survival capability in CavS
cells under suspension condition, as greater apoptosis was only
observed in CavS cells upon suspension but not under attachment
conditions (Figure 4A–C). Furthermore, the downregulation of
survivin in suspended CavS cells could also account for their
reduced anoikis resistance (Figure 4). The difference in the pattern
of cleaved caspases 8 and 9 between the EV cells treated with
integrin b1-blocking antibody (Figure 6C) and suspended CavS
cells (Figure 4C) suggests that the interaction of Cav-1 with
integrin b1 may not be sufficient to activate the intrinsic apoptosis
pathway. This inside-out signalling could be different from the
outside-in signalling induced by integrin b1-blocking antibody.
The signalling pathways activated under suspension conditions are
different from those under attachment conditions, as there are no
noticeable changes in phosphorylated integrin b1 (ser785) in
suspended CavS and EV cells treated with or without integrin b1-
blocking antibody (data not shown). There is a discrepancy
between our observations with the findings that MCF-7 cells
transfected with cav-1 cDNA exhibited increased survival after
detachment (Ravid et al, 2005). This could be that MCF-7 cells do
not have metastatic potential. Thus, the significantly lower
incidence of lung metastases in the CavS tumour-bearing mice
than in the EV-bearing mice could be the result of greater anoikis
in CavS cells occurring in the blood circulation before their
landing in the lung. Taken together, our findings are consistent
with the current views that upregulated expression of integrin b1
may play a pivotal role in metastasis development (Janes and Watt,
2006). The mechanisms by which expression of Cav-1 and its
interaction with integrins affects cell survival pathways remain to
be studied.
By using a late stage metastasis model, this study has revealed a
novel finding that Cav-1 has differential effect on lymph node and
lung metastasis. Caveolin-1 could curtail distance metastasis,
consistent with our in vitro observation that Cav-1 sensitises
metastatic cells to anoikis but not under attached condition. The
lack of difference in the incidence of LNM between EV and CavS
expressing xenograft mice suggests that M4 cells may have adapted
to be destined to metastasise to the lymph node in mice, overcoming
the inhibition exerted by Cav-1. Although regional metastasis poses
as an unfavourable prognostic factor, it is the distant metastasis that
is always incurable. Thus, the differential effect of Cav-1 observed in
the study may help shed lights on its conflicting views of prognostic
indicator. There were more than 5000 genes significantly altered in
the highly metastatic M4 cells compared with the parental
low-metastasis 686LN cells (Zhang et al, 2006), including the loss
of E-cadherin and p53, the known key players in tumour
suppression and metastasis. However, simply restoring Cav-1
expression could indeed suppress tumour growth and reduce
distant metastasis in vivo. In conclusion, our data suggested that
Cav-1 could play an inhibitory role in tumorigenesis and lung
metastasis of HNSCC through regulating integrin b1- and Src-
mediated cell–cell and cell–matrix interactions.
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